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Putation in ABCA1 Predicted Risk of Ischemic Heart
isease in the Copenhagen City Heart Study Population
uth Frikke-Schmidt, MD, PHD,* Børge G. Nordestgaard, MD, DMSC,†‡ Peter Schnohr, MD,‡
olf Steffensen, MD,§ Anne Tybjærg-Hansen, MD, DMSC,‡
openhagen, Herlev, Bispebjerg, and Hillerød, Denmark
OBJECTIVES We tested whether heterozygosity for the K776N mutation (frequency: 0.4%) in ATP-binding
cassette transporter A1 (ABCA1) predicted ischemic heart disease (IHD) in the Copenhagen
City Heart Study population.
BACKGROUND In a complex trait like IHD, genetic variation is considered to be conferred by common DNA
polymorphisms, although rare mutations may have a larger impact. Tangier disease, a rare
high-density lipoprotein cholesterol (HDL-C) deficiency syndrome with IHD, is caused by
homozygous ABCA1 mutations.
METHODS We analyzed blood samples from a large cohort study of 9,076 Danish individuals followed
for 24 years (167,287 person-years), during which 1,033 incident IHD events occurred. The
hypothesis was retested in an independent case-control study comparing 562 IHD patients
with 3,103 controls.
RESULTS The cumulative incidence of IHD as a function of age was increased in K776N heterozygotes
compared with non-carriers (log-rank test: p  0.005). At the age of 80 years, 48% of
heterozygotes and 23% of non-carriers had IHD. Incidence rates in non-carriers and K776N
heterozygotes were 61 and 157 per 10,000 person-years. The age-adjusted hazard ratio for
IHD in K776N heterozygotes versus non-carriers was 2.4 (95% confidence interval 1.3 to
4.5). Adjusting for HDL-C, or for smoking, diabetes, and hypertension did not change the
result, suggesting that genotype predicted risk of IHD beyond that offered by HDL-C, and
by other conventional risk factors. Similar trends were obtained in an independent
case-control study.
CONCLUSIONS Heterozygosity for an ABCA1 mutation (K776N) conferred two- to three-fold risk of IHD
in 37 participants in the Copenhagen City Heart study. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.0661516–20) © 2005 by the American College of Cardiology Foundation
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dhe understanding of the genetic contribution to ischemic
eart disease (IHD), the most common cause of death in
eveloped countries (1), is very limited. Rare mutations in
he heterozygous or homozygous state are known to cause
amilial hypercholesterolemia (2); however, the major ge-
etic contribution to IHD is generally considered to be
onferred by common DNA polymorphisms. Alternatively,
are mutations independent of plasma cholesterol levels may
ave a considerable impact on IHD risk (3).
The ATP-binding cassette transporter AI (ABCA1) is cru-
ial in the initial step of high-density lipoprotein (HDL)
ormation and in reverse cholesterol transport. Tangier
isease, a rare HDL deficiency syndrome (4–6) associated
ith an increased risk of IHD, is caused by homozygous
BCA1 mutations. Genetic variation in several other genes
uch as apolipoprotein AI (apoAI), apolipoprotein E, lecithin
holesteryl acyltransferase, lipoprotein lipase, hepatic lipase, and
holesteryl ester transfer protein are known to influence HDL
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ccepted June 20, 2005.holesterol levels (7,8). We and others have recently shown
hat rare ABCA1 variants contribute to HDL-C levels in the
eneral population (9,10). Thus, heterozygosity for muta-
ions in ABCA1 may influence risk of IHD in individuals in
he general population.
Functional defects of mutations in Tangier disease and
ypoalphalipoproteinemia have been extensively tested and
erified in studies of apoAI cross-linking, cholesterol efflux,
nd intracellular signal trafficking (10–12). The K776 res-
due is localized in the middle of the ABCA1 protein in a
omain that is predicted to be either transmembrane or very
lose to the extracellular surface (13); very little is known
bout the functionality of this exact area. The K776N
utation is of particular interest because: 1) K776 is
ompletely conserved between species; 2) the K  N amino
cid substitution results in a change in side chain charge
basic to uncharged polar); 3) K776N is reported to be
elatively frequent in Caucasians (3 per 1,000) (14); 4)
isease-causing mutations have been identified in the cor-
esponding region of a closely related gene, the cystic fibrosis
ransmembrane conductance regulator (CFTR or ABCC7) (15).
We tested the hypothesis that ABCA1 K776N genotype
s associated with risk of IHD in the general population.
his was studied using blood samples from 9,076 Danish
ndividuals followed for 24 years (167,287 person-years),
uring which 1,033 incident IHD events occurred. Further,
he hypothesis was retested in an independent case-control
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October 18, 2005:1516–20 Mutation in ABCA1 and IHDtudy comparing 562 IHD patients with 3,103 healthy
ontrols.
ETHODS
articipants. The Copenhagen City Heart Study is a large
ohort study of the Danish general population initiated in
976 to 1978 with follow-up examinations in 1981 to 1983
nd 1991 to 1994 (16,17). At the third examination (1991
o 1994), 16,563 individuals were invited, 10,135 partici-
ated (response rate 61%), and clinical and laboratory data,
NA, and genotype information was available on 9,140.
nformed consent was obtained from all participants, of
hich more than 99% were white and of Danish descent.
he study was approved by the Danish Ethics Committee
or the City of Copenhagen and Frederiksberg (No.
00.2039/91). To begin to verify the findings in the cohort
tudy, 562 patients (45 to 64 years old) with IHD verified by
oronary angiography at Department of Cardiology,
openhagen University Hospital, Rigshospitalet, were
ompared with 3,103 healthy controls within the same age
ange.
tudy designs. The 9,140 participants were followed from
ntry at the first (1976 to 1978), second (1981 to 1983), or
hird (1991 to 1994) examinations, and until end of follow-
p, December 31, 1999. Information on diagnoses of IHD
World Health Organization International Classification of
iseases, 8th edition, codes 410 to 414; 10th edition, I20 to
25) was gathered until 1999 from the Danish National
ospital Discharge Register, from the Danish National
egister of Causes of Death, and from medical records of
eneral practitioners and hospitals. Of the 1,097 partici-
ants recorded with IHD, 64 were diagnosed before entry
nto the Copenhagen City Heart Study and were excluded,
eaving 1,033 incident IHD cases, and a total of 9,076
ndividuals for all further analyses. Median follow-up time
as 22 years (range, 0.04 to 24 years), representing 167,287
erson-years. Follow-up was 99.9% complete.
Risk factors for IHD (i.e., diabetes mellitus, smoking,
nd hypertension) were dichotomized and defined as ever-
iabetics (self-reported disease, use of insulin, use of oral
ypoglycemic drugs, and/or non-fasting plasma glucose
11.1 mmol/l at any of the three examinations), ever-
mokers (ex-smoker or current smoker at any of the three
xaminations), ever-hypertensive (systolic blood pressure
140 mm Hg or diastolic blood pressure 90 mm Hg or
se of antihypertensive drugs at any of the three examina-
Abbreviations and Acronyms
apoAI  apolipoprotein AI
CFTR  cystic fibrosis transmembrane conductance
regulator
HDL-C  high-density lipoprotein cholesterol
IHD  ischemic heart diseaseions). KNA analyses. An ABI PRISM 7900HT Sequence De-
ection System (Applied Biosystems, Foster City, Califor-
ia) was used to genotype the K776N (nucleotide 2327G 
) mutation. TaqMan Universal PCR Master Mix
Applied Biosystems), wild-type and mutation-specific
aqMan probes (wild-type reporter probe: VIC-CA-
TCAAGATCTTCGC, mutation reporter probe: FAM-
CTCAACATCTTCGC), and one pair of polymerase
hain reaction primers were used (forward: 5=TGTG-
CATGGCAGGACTAC, reverse: 5=AGAAAGGC-
AGAGGTACTCACA). A perfectly hybridized probe is
leaved by the 5=nuclease activity of Taq polymerase, releas-
ng the 3=quencher linked to the probe, and resulting in a
robe-specific increase in fluorescence. The assay was ob-
ained from the Assay-by-Design Service using the Assay-
y-Design File Builder software from Applied Biosystems.
ther analyses. Colorimetric and turbidimetric assays
ere used to measure plasma levels of total cholesterol,
DL-C, triglycerides, and apolipoproteins B and AI (all
oehringer Mannheim, Mannheim, Germany).
tatistical analyses. We used the statistical software pack-
ge Stata (STATA Corp., College Station, Texas). Two-
ided probability values 0.05 were considered significant.
earson chi-square test and Student t test were used for
wo-group comparisons. Cox proportional hazards regres-
ion models estimated hazard ratios for IHD as a function
f K776N genotype, and Kaplan-Meier plots and log-rank
ests evaluated the cumulative incidence of IHD as a
unction of age and K776N genotype. For all survival
tatistics, age was the time scale using left truncation (or
elayed entry). When age is used with left truncation, it
mplies that age is automatically adjusted for, and therefore
ot included as a covariate in the model (18). The assump-
ion of proportional hazard ratios was checked by visual
nspection of graphs of the log of the cumulative hazard
unction in the exposed and unexposed groups. If these
raphs for the exposed and unexposed groups are parallel,
he assumption is not violated. Smoking, diabetes, and
ypertension dichotomized, and HDL-C in tertiles were
orced into the regression models. Hazard ratios are pre-
ented for heterozygotes versus non-carriers, because no
omozygotes were identified. Logistic regression analysis
djusted for age in 10-year age groups estimated odds ratio
or IHD in the case-control study.
ESULTS
mong the 9,076 participants in The Copenhagen City
eart Study, 37 (frequency: 0.4%) were heterozygous and
one were homozygous for K776N. Genotype frequencies
id not differ from those predicted by the Hardy-Weinberg
quilibrium (p  0.85). Risk factors for IHD did not differ
etween non-carriers and K776N heterozygotes, except for
evels of HDL-C in men (Table 1). The cumulative
ncidence of IHD as a function of age was increased in
776N heterozygotes compared with non-carriers (log-
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Mutation in ABCA1 and IHD October 18, 2005:1516–20ank test: p  0.005) (Fig. 1). At the age of 80 years, about
8% of heterozygotes and 23% of non-carriers had IHD.
ncidence rates in non-carriers and K776N heterozygotes
ere 61 and 157 per 10,000 person-years (Table 2). The
ge-adjusted hazard ratio for IHD in K776N heterozygotes
ersus non-carriers was 2.4 (95% confidence interval 1.3 to
.5) (Table 2). Adjusting for HDL-C, or for smoking,
iabetes, and hypertension did not substantially change the
azard ratio, suggesting that genotype predicted risk of
HD beyond that offered by HDL-C, and by other con-
entional risk factors. Finally, in an independent case-
ontrol study comparing 562 patients with IHD with 3,103
ealthy controls within the same age range, the odds ratio
or IHD in K776N heterozygotes versus non-carriers was
.8 (95% confidence interval 0.8 to 9.4) (Table 3).
Mean plasma HDL-C in non-carriers and K776N het-
rozygotes was 1.72 mmol/l and 1.82 mmol/l in women (p
0.42), and 1.38 mmol/l and 1.18 mmol/l in men (p 
.05). Mean plasma apoAI levels in non-carriers and
776N heterozygotes were 151 mg/dl and 150 mg/dl in
omen (p 0.93), and 130 mg/dl and 117 mg/dl in men (p
0.03) (data not shown); HDL-C levels in the 37
ndividuals heterozygous for K776N ranged from 1.0 to 2.7
mol/l in women, and from 0.5 to 2.0 mmol/l in men.
hree of 19 women (16%), and 6 of 18 men (33%) had
on-fasting triglycerides 2.2 mmol/l. Five of 19 women
26%) and 5 of 18 men (28%) had IHD; of these, one
oman and one man had premature IHD, and two men had
schemic stroke.
ISCUSSION
total of 20% to 44% of Tangier disease patients have been
eported to have cardiovascular disease compared with only
% to 6% in control populations (19). Heterozygotes for
angier disease do not have the classical Tangier symptoms
aused by massive deposition of cholesteryl esters in various
issues, in particular tonsil anomalies and neuropathy are not
haracteristic. Biochemically heterozygotes are sometimes,
ut not always, characterized by half-normal serum concen-
able 1. Characteristics of Individuals in the General Population
Women
Non-Carriers
(n  5,003)
K776N
(
ge at entry (yrs) 46  0.2 4
holesterol (mmol/l) 6.3  0.02 6
polipoprotein B (mg/dl) 86.4  0.3 83
DL-C (mmol/l) 1.72  0.01 1.8
riglycerides (mmol/l) 1.7  0.02 1
ody mass index (kg/m2) 25.2  0.07 25
moking (%) 73
iabetes mellitus (%) 3
ypertension (%) 51
alues are mean  SE, or percentages. Non-normally distributed variables were tr
ompared with non-carriers by Pearson chi-square test or Student t test. *p  0.05.
HDL-C  high-density lipoprotein cholesterol.rations of HDL-C, and by apoAI levels below the fifth
F
fercentile of sex-matched controls (20), but it is unclear at
resent whether heterozygotes for mutations in ABCA1
ave an increased risk of IHD, and whether this risk is
orrelated to HDL-C levels. The frequency of IHD in
776N heterozygotes in the present study was 26% to 28%
women: 5 of 19; men: 5 of 18), comparable to the
requency in Tangier disease. A heterozygous mutation in
BCA1 in the Copenhagen City Heart Study population
redicted risk of IHD independent of plasma HDL-C. The
resent study supports experimental evidence that ABCA1
ay have antiatherosclerotic or anti-ischemic properties
ndependent of plasma HDL-C (21–24). Thus, risk of IHD
n individuals homozygote or heterozygote for mutations in
BCA1 may not only be related to levels of HDL-C in
lasma, but may also depend on local effects of ABCA1
utations in the arterial wall (21–23) or in platelets (24),
romoting atherosclerosis.
The K776 residue is localized in the middle part of the
BCA1 protein in a fragment that is predicted to be either
ransmembrane, or very close to the extracellular surface
13). Very little is known about the functionality of this
xact area. In contrast, the two major extracellular loops
11,12), the ATP-binding cassettes, a regulatory proline-
lutamic acid-serine-threonine (PEST) sequence (residues
283 to 1306) (25,26), and the C-terminal region have been
xtensively studied (27). A rare single nucleotide polymor-
hism (SNP) (V771M, allele frequency 0.03) and a muta-
BCA1 K776N Genotype
Men
rozygotes
9)
Non-Carriers
(n  4,036)
K776N Heterozygotes
(n  18)
3.0 45  0.2 48  2.5
0.3 6.0  0.02 5.6  0.3
5.3 86.2  0.3 85.1  6.2
0.11 1.38  0.01 1.18  0.09*
0.2 2.1  0.03 2.3  0.3
1.0 26.1  0.06 24.7  1.1
84 88
6 11
59 56
med before comparisons; untransformed values are presented. Heterozygotes wereby A
Hete
n  1
5 
.2 
.8 
2 
.4 
.0 
89
0
37
ansforigure 1. Cumulative incidence of ischemic heart disease (IHD) as a
unction of age and ABCA1 K776N genotype.
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October 18, 2005:1516–20 Mutation in ABCA1 and IHDion (T774P, allele frequency 0.004) situated, respectively,
ve and two amino acids N-terminal of the K776 residue,
ave been reported. Although we have recently shown that
771M is associated with increased HDL-C levels (9),
ffects on risk of IHD have not been documented for either
f these variants (14,28). In contrast to the V771 and K776
esidues, T774 is not conserved between species. The high
egree of conservation of K776 between species and be-
ween human ABCAs with very different transport func-
ions could indicate that this part of the protein is essential
or normal function. To our knowledge, no homozygotes for
776N have been described so far, and we also did not
dentify any. Mean HDL-C levels in heterozygotes were
.82 mmol/l (range: 1.0 to 2.7 mmol/l) in women, and 1.18
mol/l (range: 0.5 to 2.0 mmol/l) in men. It is therefore
nlikely that the majority of K776N homozygotes would
xpress an HDL-C deficiency phenotype comparable to
angier disease, where HDL-C levels are generally below
.2 mmol/l. However, as is the case for K776N in the
resent study, in Tangier disease there also does not seem to
e a clear correlation between the reduction in plasma
DL-C levels and risk of IHD. This is in agreement with
revious studies that did not determine genetic variation in
BCA1 as strong predictors of HDL-C (9,14,29). A likely
eason for this is that ABCA1 mainly affects pre-beta HDL,
type of HDL very poor in cholesterol content. However,
his does not preclude an effect of genetic variants in ABCA1
n risk of IHD.
Although K776N is a relatively common mutation, it is
ot a common cause of IHD. The population-attributable
raction of K776N to IHD is about 0.4% in the Copenha-
en City Heart Study, or comparable to the risk of IHD
ttributed to low-density lipoprotein receptor mutations in
he same study. However, at the individual level, K776N
ppears to have a marked impact on risk.
As this is a novel observation, it may represent a chance
nding. However, several arguments favor a true observa-
able 2. Risk of Ischemic Heart Disease as a Function of ABCA1
Events
Incidence Rate/1
Person-Years (95%Observed Expected
on-carriers 1,023 1,029 61 (58–65)
776N heterozygotes 10 4 157 (76–290)
n the Cox regression model (age-adjusted, HDL-C–adjusted, and multifactorial-
runcation). HDL-C–adjusted: HDL-C in tertiles. Multifactorial adjusted: smoking
CI  confidence interval; HDL-C  high-density lipoprotein cholesterol.
Table 3. Risk of Ischemic Heart Disease as a F
Case-Control Study
IHD
All Non-carriers 558 (99
K776N heterozygotes 4 (0.7
A total of 562 45-to 64-year-old patients with ischemic hea
with 3,103 healthy controls within the same age range.
CI  confidence interval.ion: 1) the involved amino acid residue is completely
onserved between species and relatively conserved between
2 ABCAs with very different transport functions; 2) the
mino acid substitution changes the charge of the side-
hain, potentially leading to structural alterations of the
rotein, and consequently to altered protein interactions or
ransport properties; 3) in the CFTR (or ABCC7), a disease-
ausing mutation (R347P) has been identified at a site that
orresponds to residue 764 in ABCA1 (15), and thus in close
icinity to K776N; 4) the present study is of a large cohort,
nd therefore includes only incident cases, avoiding the
ormal pitfalls of case reports and case-control studies (30);
) we observed a similar trend on risk of IHD in a separate
ase-control study; 6) we have previously determined effects
n lipids and lipoproteins of all non-synonymous SNPs
dentified in ABCA1 (R219K, V771M, V825I, I883M,
1172D, R1587K). When taking multiple testing into
ccount, the log-rank test for the cumulative incidence of
schemic heart disease as a function of age and K776N
enotype fulfilled a Bonferroni-corrected p value 0.007
0.05 of 7) on a two-sided test (seven different genetic
ariants tested including K776N).
The fact that DNA samples were not obtained before the
991 to 1994 examination is a source of potential bias. If
ortality rate from ischemic heart disease was higher
mong K776N heterozygotes and homozygotes than among
on-carriers, our study would underestimate the association
etween ABCA1 K776N and risk of ischemic heart disease.
owever, the fact that K776N was in Hardy-Weinberg
quilibrium suggested that no serious selection bias had
ccurred in the cohort during follow-up.
This study demonstrated that heterozygosity for a com-
on mutation in ABCA1 increased risk of IHD in the
openhagen City Heart Study population, and predicted
isk of IHD beyond traditional cardiovascular risk factors.
dditional large cohort studies should address whether the
6N Genotype in the General Population
Hazard Ratio (95% CI)
Age-Adjusted HDL-C–Adjusted Multifactorial-Adjusted
1 1 1
2.4 (1.3–4.5) 2.4 (1.3–4.5) 2.4 (1.3–4.5)
d), age is adjusted for by incorporating age in the baseline hazard function (left
tes mellitus, and hypertension dichotomized.
ion of ABCA1 K776N Genotype in the
equency
Odds Ratio (95% CI)
Age-AdjustedControls
3,095 (99.7) 1
8 (0.3) 2.8 (0.8–9.4)
ase (IHD) verified by coronary angiography were comparedK77
0,000
CI)
adjusteunct
Fr
.3)
)
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